{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:30Z","timestamp":1761896370732},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T00:00:00Z","timestamp":1469836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00277-016-2771-2","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T23:36:11Z","timestamp":1469835371000},"page":"1917-1918","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma"],"prefix":"10.1007","volume":"95","author":[{"given":"Thomas S. Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pek-Lan","family":"Khong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,30]]},"reference":[{"issue":"28","key":"2771_CR1","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2012.43.5800","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439\u20133443","journal-title":"J Clin Oncol"},{"issue":"8","key":"2771_CR2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00277-014-2116-y","volume":"93","author":"A Carbone","year":"2014","unstructured":"Carbone A, Gloghini A, Kwong YL, Younes A (2014) Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 93(8):1263\u20131277","journal-title":"Ann Hematol"},{"issue":"4","key":"2771_CR3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","volume":"170","author":"C Howlett","year":"2015","unstructured":"Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A (2015) Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 170(4):504\u2013514","journal-title":"Br J Haematol"},{"key":"2771_CR4","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Snyder E, Marinello P, Shipp MA, Armand P (2015) Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma (PMBCL). 4: Blood, Absract 3986","DOI":"10.1182\/blood.V126.23.3986.3986"},{"key":"2771_CR5","doi-asserted-by":"crossref","unstructured":"Ding W, Dong H, Call TG, Shanafelt TD, Parikh SA, Leis JF, Laplant BR, He R, Witzig TE, Lin Y, Chanan-Khan A, Bowen DA, Conte M, Habermann TM, Viswanatha D, Micallef I, Kay NE, Ansell S (2015) Blockade with pembrolizumab (MK-3475) in relapsed\/refractory CLL including Richter transformation: an early efficacy report from a phase 2 trial (MC1485). Blood, Abstract 834","DOI":"10.1182\/blood.V126.23.834.834"},{"issue":"3","key":"2771_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, Laplant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33(3):251\u2013257","journal-title":"J Clin Oncol"},{"issue":"25","key":"2771_CR7","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33(25):2803\u20132811","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2771-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2771-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:27:30Z","timestamp":1600961250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2771-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,30]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2771"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2771-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,30]]}}}